NYSE:GKOSMedical Equipment
Is Glaukos (GKOS) Undervalued Following Record Sales And Higher 2026 Guidance?
Glaukos (GKOS) is back in focus after reporting record second quarter net sales, supported by iDose TR and the Epioxa launch, and raising its full year 2026 net sales guidance.
See our latest analysis for Glaukos.
The earnings beat and higher 2026 sales guidance have fed into strong momentum for Glaukos, with a 30 day share price return of 17.69% and year to date share price return of 62.59%. Over a longer horizon, the 1 year total shareholder return of 112.66% suggests recent enthusiasm has...